Interstitial lung disease occurred in 49 patients (11.3%; three events had grade 5 severity) and pneumonitis occurred in one patient (0.2%; grade 2).
In patients with HER2-low disease, the median PFS was 13.2 months (95% CI, 11.4–15.2) in the trastuzumab deruxtecan group and 8.1 months (95% CI, 7.0–9.0) in the chemotherapy group (HR, 0.62; 95% CI, 0.51–0.74;P< .001).[55][Level of evidence B1] Grade 3 or higher adverse events occurred in 52.8% of patients in the trastuzumab deruxtecan group and 44.4% of patients in the chemotherapy group.
Interstitial lung disease occurred in 49 patients (11.3%; three events had grade 5 severity) and pneumonitis occurred in one patient (0.2%; grade 2).